Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Trevi Therapeutics, Inc. - Common Stock (NQ:TRVI)

14.46 +0.04 (+0.24%)
Streaming Delayed Price Updated: 1:55 PM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 926,501
Open 14.48
Bid (Size) 14.44 (500)
Ask (Size) 14.47 (600)
Prev. Close 14.42
Today's Range 14.27 - 14.77
52wk Range 8.455 - 20.22
Shares Outstanding 60,069,512
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Trevi Therapeutics Q2 Earnings Call Highlights ↗
Trevi Therapeutics (NASDAQ:TRVI) said it began two clinical trials during the second quarter and plans to launch a third study in the third quarter as it advances nalbuphine ER, also known as Haduvio,... 
Via MarketBeat
Topics Earnings
News headline image
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+21.6%
+21.6%
1 Month
-12.9%
-12.9%
3 Month
-22.5%
-22.5%
6 Month
+21.2%
+21.2%
1 Year
+61.5%
+61.5%

More News

Read More
News headline image
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030 ↗
Via MarketBeat
Trevi Therapeutics Inc. (NASDAQ:TRVI) Beats Q4 2025 EPS Estimates, Gains FDA Alignment for Phase 3 Program ↗
Via Chartmill
News headline image
Earnings Scheduled For November 13, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
Via Benzinga
News headline image
Earnings Preview For Trevi Therapeutics ↗
Via Benzinga
News headline image
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗
Via The Motley Fool
News headline image
Trevi Therapeutics (TRVI) Earnings Transcript ↗
Via The Motley Fool
News headline image
TRVI Stock Slips After Company Plans Parallel Trials In Lung Disease — Stifel Dismisses Timeline Concerns ↗
Via Stocktwits
News headline image
MarketBeat’s Top 5 Rated Small-Cap Stocks ↗
Via MarketBeat
News headline image
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
Via The Motley Fool
Topics Lawsuit Regulatory Compliance
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
Via The Motley Fool
Topics Lawsuit Regulatory Compliance
News headline image
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Trevi Therapeutics Inc (NASDAQ:TRVI) Reports Q3 2025 Results, Narrows Loss and Outlines Phase 3 Plans ↗
Via Chartmill
News headline image
A Peek at Trevi Therapeutics's Future Earnings ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
Via Benzinga
News headline image
This Adient Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
Via Benzinga
News headline image
Dow Gains Over 100 Points; US Job Openings Increase In April ↗
Via Benzinga
Topics Stocks
News headline image
Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients ↗
Via Benzinga
News headline image
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
From Avalo Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Trevi Therapeutics, Inc. - Common Stock publicly traded?
Yes, Trevi Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Trevi Therapeutics, Inc. - Common Stock trade on?
Trevi Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Trevi Therapeutics, Inc. - Common Stock?
The ticker symbol for Trevi Therapeutics, Inc. - Common Stock is TRVI on the Nasdaq Stock Market
What is the current price of Trevi Therapeutics, Inc. - Common Stock?
The current price of Trevi Therapeutics, Inc. - Common Stock is 14.46
When was Trevi Therapeutics, Inc. - Common Stock last traded?
The last trade of Trevi Therapeutics, Inc. - Common Stock was at 09/30/26 01:55 PM ET
What is the market capitalization of Trevi Therapeutics, Inc. - Common Stock?
The market capitalization of Trevi Therapeutics, Inc. - Common Stock is 868.30M
How many shares of Trevi Therapeutics, Inc. - Common Stock are outstanding?
Trevi Therapeutics, Inc. - Common Stock has 868M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.